May 1, 1989European Heart Journal
Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies
Authors
Discussion
Loading...
Member takes
Implication
May support metoprolol in diabetic AMI; leaves open prospective confirmation before practice change.
Key Points
- To evaluate the impact of metoprolol versus placebo on mortality and late infarction in diabetic patients presenting with suspected acute myocardial infarction.
- Retrospective analysis evaluating diabetic subgroup outcomes from two large-scale clinical trials: the Göteborg Metoprolol Trial and the MIAMI Trial.
- Patients received either metoprolol or placebo following suspected acute myocardial infarction, with follow-up durations of 3 months (Göteborg) and 15 days (MIAMI).
- In the Göteborg Metoprolol Trial, metoprolol reduced 3-month mortality from 17.9% to 7.5% and late infarction from 16.4% to 3.8% compared with placebo.
- In the MIAMI Trial, metoprolol decreased 15-day mortality from 11.3% to 5.7% and late infarction from 4.5% to 3.1% compared with placebo.
Cite This Study
Malmberg et al. (1989) studied this question.